Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Molecular Analysis for Therapy Choice (MATCH)

Trial Profile

Molecular Analysis for Therapy Choice (MATCH)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adavosertib (Primary) ; Afatinib (Primary) ; AZD 4547 (Primary) ; Binimetinib (Primary) ; Capivasertib (Primary) ; Copanlisib (Primary) ; Crizotinib (Primary) ; Dabrafenib (Primary) ; Dasatinib (Primary) ; Defactinib (Primary) ; Erdafitinib (Primary) ; GSK 2636771 (Primary) ; Ipatasertib (Primary) ; Larotrectinib (Primary) ; Nivolumab (Primary) ; Osimertinib (Primary) ; Palbociclib (Primary) ; Pertuzumab (Primary) ; Sapanisertib (Primary) ; Sunitinib (Primary) ; Taselisib (Primary) ; Trametinib (Primary) ; Trastuzumab emtansine (Primary) ; Ulixertinib (Primary) ; Vismodegib (Primary)
  • Indications Adenoid cystic carcinoma; Advanced breast cancer; Anal cancer; Bladder cancer; Cervical cancer; Cholangiocarcinoma; Endometrial cancer; Glioblastoma; Head and neck cancer; Leiomyosarcoma; Lung cancer; Lymphoma; Multiple myeloma; Oesophageal cancer; Prostate cancer; Solid tumours; Squamous cell cancer; Urogenital cancer; Uterine cancer
  • Focus Therapeutic Use
  • Acronyms MATCH; NCI-MATCH
  • Most Recent Events

    • 25 Nov 2019 Results from Arm Z1D-A Subprotocol of the NCI-MATCH published in the Journal of Clinical Oncology
    • 30 Oct 2019 Baseline charecteristich for adolescent and young adult cohort (n=373) presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019.
    • 27 Aug 2019 Results of patients from subprotocol Q (n=38) published in the Annals of Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top